Login
$HOWL
$0.99 +$0.01 (1.07%) Live

$HOWL SEC Filings

Filed On Filing
13 Nov 2026 10-Q
12 Nov 2026 EFFECT
12 Nov 2026 424B3
10 Nov 2026 S-4/A
10 Nov 2026 425
09 Nov 2026 8-K: Regulation FD Disclosure

Werewolf Therapeutics’ Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting

26 Oct 2026 REGISTRATION OF SECURITIES ISSUED IN BUSINESS COMBINATION TRANSACTIONS
22 Sep 2026 S-4
21 Sep 2026 SCHEDULE 13G
21 Aug 2026 425
21 Aug 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more

THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) is made and entered into as of August 21, 2026, by and among AMBROS THERAPEUTICS, INC., a Delaware corporation (“Ambros”), WEREWOLF THERAPEUTICS, INC., a Delaware corporation (“Werewol...

20 Aug 2026 8-K: Entry into a Material Definitive Agreement

On August 14, 2026 (the “Closing”), Werewolf Therapeutics, Inc. (the “Company”) entered into an asset purchase agreement (the “Purchase Agreement”) with EMD Serono Research & Development Institute Inc. (“EMD”), pursuant to which, and sub...

31 Jul 2026 10-Q
31 Jul 2026 8-K: Results of Operations and Financial Condition

Watertown, Mass., July 31, 2026 (GLOBE NEWSWIRE) – Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engin...

08 Jul 2026 Form 4: Evnin Luke, Director

Sold 35,770 shares ($11.4K) · Sold 107,429 shares ($33.3K)

06 Jul 2026 144
06 Jul 2026 144
06 Jul 2026 144
06 Jul 2026 144
06 Jul 2026 144

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support